157 related articles for article (PubMed ID: 16081543)
21. Competitive binding to a charged leucine motif represses transformation by a papillomavirus E6 oncoprotein.
Bohl J; Das K; Dasgupta B; Vande Pol SB
Virology; 2000 May; 271(1):163-70. PubMed ID: 10814581
[TBL] [Abstract][Full Text] [Related]
22. The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation.
Antonsson A; Payne E; Hengst K; McMillan NA
J Interferon Cytokine Res; 2006 Jul; 26(7):455-61. PubMed ID: 16800784
[TBL] [Abstract][Full Text] [Related]
23. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
Rampias T; Sasaki C; Weinberger P; Psyrri A
J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
[TBL] [Abstract][Full Text] [Related]
24. Targeting mechanism of the retinoblastoma tumor suppressor by a prototypical viral oncoprotein. Structural modularity, intrinsic disorder and phosphorylation of human papillomavirus E7.
Chemes LB; Sánchez IE; Smal C; de Prat-Gay G
FEBS J; 2010 Feb; 277(4):973-88. PubMed ID: 20088881
[TBL] [Abstract][Full Text] [Related]
25. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells.
Banks L; Edmonds C; Vousden KH
Oncogene; 1990 Sep; 5(9):1383-9. PubMed ID: 2216461
[TBL] [Abstract][Full Text] [Related]
26. Cooperative transformation and coexpression of bovine papillomavirus type 1 E5 and E7 proteins.
Bohl J; Hull B; Vande Pol SB
J Virol; 2001 Jan; 75(1):513-21. PubMed ID: 11119620
[TBL] [Abstract][Full Text] [Related]
27. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein.
Brokaw JL; Yee CL; Münger K
Virology; 1994 Dec; 205(2):603-7. PubMed ID: 7975265
[TBL] [Abstract][Full Text] [Related]
28. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein.
Phelps WC; Münger K; Yee CL; Barnes JA; Howley PM
J Virol; 1992 Apr; 66(4):2418-27. PubMed ID: 1312637
[TBL] [Abstract][Full Text] [Related]
29. Notch1 can contribute to viral-induced transformation of primary human keratinocytes.
Lathion S; Schaper J; Beard P; Raj K
Cancer Res; 2003 Dec; 63(24):8687-94. PubMed ID: 14695182
[TBL] [Abstract][Full Text] [Related]
30. The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango.
Talbert-Slagle K; DiMaio D
Virology; 2009 Feb; 384(2):345-51. PubMed ID: 18990418
[TBL] [Abstract][Full Text] [Related]
31. The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis.
Rapp L; Liu Y; Hong Y; Androphy EJ; Chen JJ
Oncogene; 1999 Jan; 18(3):607-15. PubMed ID: 9989810
[TBL] [Abstract][Full Text] [Related]
32. Identification of a second transforming function in bovine papillomavirus type 1 E6 and the role of E6 interactions with paxillin, E6BP, and E6AP.
Das K; Bohl J; Vande Pol SB
J Virol; 2000 Jan; 74(2):812-6. PubMed ID: 10623743
[TBL] [Abstract][Full Text] [Related]
33. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation.
Weijzen S; Zlobin A; Braid M; Miele L; Kast WM
J Cell Physiol; 2003 Mar; 194(3):356-62. PubMed ID: 12548555
[TBL] [Abstract][Full Text] [Related]
34. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.
Brehm A; Nielsen SJ; Miska EA; McCance DJ; Reid JL; Bannister AJ; Kouzarides T
EMBO J; 1999 May; 18(9):2449-58. PubMed ID: 10228159
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity.
Massimi P; Pim D; Banks L
J Gen Virol; 1997 Oct; 78 ( Pt 10)():2607-13. PubMed ID: 9349482
[TBL] [Abstract][Full Text] [Related]
36. Negative regulation of the bovine papillomavirus E5, E6, and E7 oncogenes by the viral E1 and E2 genes.
Vande Pol SB; Howley PM
J Virol; 1995 Jan; 69(1):395-402. PubMed ID: 7983735
[TBL] [Abstract][Full Text] [Related]
37. Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53.
Zimmermann H; Koh CH; Degenkolbe R; O'Connor MJ; Müller A; Steger G; Chen JJ; Lui Y; Androphy E; Bernard HU
J Gen Virol; 2000 Nov; 81(Pt 11):2617-2623. PubMed ID: 11038372
[TBL] [Abstract][Full Text] [Related]
38. High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins.
Havard L; Rahmouni S; Boniver J; Delvenne P
Virology; 2005 Jan; 331(2):357-66. PubMed ID: 15629778
[TBL] [Abstract][Full Text] [Related]
39. Mutagenic Potential ofBos taurus Papillomavirus Type 1 E6 Recombinant Protein: First Description.
Araldi RP; Mazzuchelli-de-Souza J; Modolo DG; de Souza EB; de Melo TC; Spadacci-Morena DD; Magnelli RF; de Carvalho MA; de Sá Júnior PL; de Carvalho RF; Beçak W; Stocco Rde C
Biomed Res Int; 2015; 2015():806361. PubMed ID: 26783529
[TBL] [Abstract][Full Text] [Related]
40. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
